Desert Mountain Energy - CEO, Robert Rohlfing.
CEO, Robert Rohlfing.
Source: Desert Mountain Energy.
  • Desert Mountain (DME) has completed testing at its McCauley Helium Processing Facility in Arizona
  • Commissioning of the facility is planned for January 2023
  • Upcoming production coincides with a global helium shortage due to declining U.S. output, as well as Russian curtailment due to the conflict in Ukraine
  • Desert Mountain Energy is focused on the exploration, development and production of helium, hydrogen and noble gases
  • Desert Mountain (DME) closed down by 4.06 per cent, trading at $3.07 per share

Desert Mountain (DME) has completed testing at its McCauley Helium Processing Facility in Arizona.

The company is removing temporary interconnect lines, and modular units are ready for transport.

It expects to have all of the units on-site by December 16, 2022.

All necessary equipment, such as cranes, has been scheduled to be on-site to lift modular housing onto the prepared foundations.

The team will continue to advance site fabrication and welding of the high-pressure inter-module lines.

Commissioning of the facility is planned for January 2023, which aligns with an ongoing global helium shortage due to the Russia-Ukraine conflict and U.S. domestic policy regarding the industry.

“We are very proud of what our team has accomplished over the last two years,” stated Robert Rohlfing, CEO of Desert Mountain Energy. “Like most companies, we faced delays but made strategic management decisions, like purchasing our own trucking fleet, in order to reduce the impact. We look forward to producing helium and providing it to domestic end-users throughout the helium shortage.”

Desert Mountain Energy is focused on the exploration, development and production of helium, hydrogen and noble gases.

Desert Mountain (DME) closed down by 4.06 per cent, trading at $3.07 per share.


More From The Market Online
stock market down

@ the Bell: TSX hits near-month high

The TSX rose near highs not seen in a month, but a split between indices capped gains as mining and energy were the only…

FSD Pharma submits MS treatment clinical trial for review in Australia

FSD Pharma (CSE:HUGE) submits its MS treatment's Phase-1 Multiple Ascending Doses Clinical Trial Application for ethics review in Australia.

Cloud DX signs fourth contract with a provincial health authority

Cloud DX (TSXV:CDX) signs its fourth contract with a provincial health authority for remote patient monitoring.

International Petroleum stock rallies on Q1 results

Canadian energy stock International Petroleum Corp. (TSX:IPCO) rose in Tuesday trading on its Q1 2024 financial...